WO2014144572A3 - Substrate profiling of proteases in neutrophil extracellular traps - Google Patents

Substrate profiling of proteases in neutrophil extracellular traps Download PDF

Info

Publication number
WO2014144572A3
WO2014144572A3 PCT/US2014/029040 US2014029040W WO2014144572A3 WO 2014144572 A3 WO2014144572 A3 WO 2014144572A3 US 2014029040 W US2014029040 W US 2014029040W WO 2014144572 A3 WO2014144572 A3 WO 2014144572A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteases
neutrophils
neutrophil extracellular
extracellular traps
substrate profiling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/029040
Other languages
French (fr)
Other versions
WO2014144572A2 (en
Inventor
Ye Jin
John Murphy
Terry Hermiston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Priority to CN201480015786.2A priority Critical patent/CN105339780A/en
Priority to HK16102826.8A priority patent/HK1214863A1/en
Priority to JP2016502967A priority patent/JP2016519761A/en
Priority to US14/771,322 priority patent/US9958459B2/en
Priority to EP14762263.3A priority patent/EP2997352A4/en
Priority to CA2906124A priority patent/CA2906124A1/en
Publication of WO2014144572A2 publication Critical patent/WO2014144572A2/en
Publication of WO2014144572A3 publication Critical patent/WO2014144572A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Provided herein are protein biomarkers for NETosis related diseases, including proteases. Also provided are substrate sequences of such proteases and uses thereof. Neutrophils are the most abundant leukocytes in plasma. They are the first cells recruited to injury sites in response to pathogen invasion, and they act in the first line of innate immune defense. Neutrophils have traditionally been considered effector cells for inflammatory response and acute immunity, functioning through intracellular phagocytosis, and using lytic proteases, reactive oxygen species (ROS) and microbicidal proteins for attack of infective agents.
PCT/US2014/029040 2013-03-15 2014-03-14 Substrate profiling of proteases in neutrophil extracellular traps Ceased WO2014144572A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN201480015786.2A CN105339780A (en) 2013-03-15 2014-03-14 Substrate properties of proteases in neutrophil extracellular traps
HK16102826.8A HK1214863A1 (en) 2013-03-15 2014-03-14 Substrate profiling of proteases in neutrophil extracellular traps
JP2016502967A JP2016519761A (en) 2013-03-15 2014-03-14 Substrate profiling of proteases in neutrophil extracellular traps
US14/771,322 US9958459B2 (en) 2013-03-15 2014-03-14 Application of N-terminomics to NETosis in inflammation
EP14762263.3A EP2997352A4 (en) 2013-03-15 2014-03-14 Substrate profiling of proteases in neutrophil extracellular traps
CA2906124A CA2906124A1 (en) 2013-03-15 2014-03-14 Substrate profiling of proteases in neutrophil extracellular traps

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361799658P 2013-03-15 2013-03-15
US61/799,658 2013-03-15

Publications (2)

Publication Number Publication Date
WO2014144572A2 WO2014144572A2 (en) 2014-09-18
WO2014144572A3 true WO2014144572A3 (en) 2014-11-06

Family

ID=51538342

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/029040 Ceased WO2014144572A2 (en) 2013-03-15 2014-03-14 Substrate profiling of proteases in neutrophil extracellular traps

Country Status (7)

Country Link
US (1) US9958459B2 (en)
EP (1) EP2997352A4 (en)
JP (1) JP2016519761A (en)
CN (1) CN105339780A (en)
CA (1) CA2906124A1 (en)
HK (1) HK1214863A1 (en)
WO (1) WO2014144572A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3607320A4 (en) 2017-04-03 2021-04-21 The Regents of the University of California COMPOSITIONS AND METHODS FOR DIAGNOSING PANCREE CANCER
CA3181285A1 (en) * 2020-07-20 2022-01-27 Jessica BASSO Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions
CN116438456A (en) 2020-09-11 2023-07-14 格里姆普斯生物股份有限公司 Ex vivo protease activity assays for disease detection/diagnosis, staging, monitoring and treatment
CN113238050A (en) * 2021-02-20 2021-08-10 吴炜 Rapid detection method of neutrophil extracellular trapping net
CN113310963B (en) * 2021-05-31 2023-12-01 四川大学华西医院 An improved immunofluorescence detection method for neutrophil NETs
CN115267172A (en) * 2022-07-29 2022-11-01 首都医科大学宣武医院 Application of substance for detecting NSPs (non-responsive substance) level in preparation of product for predicting prognosis of acute ischemic stroke patient

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104479A1 (en) * 2001-08-01 2003-06-05 Cellomics, Inc. Novel fusion proteins and assays for molecular binding
US20080213800A1 (en) * 2004-05-20 2008-09-04 Astellas Pharma Inc. Method for Examing Interstitital Cystitis
WO2010022281A1 (en) * 2008-08-20 2010-02-25 Greystone Pharmaceuticals, Inc. Methods for using human neutrophil elastase as an indicator of active wound infection
US20110082155A1 (en) * 2009-10-02 2011-04-07 Astrazeneca Ab Novel 2-Pyridone Compounds
US20120135443A1 (en) * 2009-06-26 2012-05-31 Schultz Gregory S Rapid Bed-Side Measurement of Neutrophil Elastase Activity in Biological Fluids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8569275B2 (en) * 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
WO2006084210A2 (en) * 2005-02-04 2006-08-10 Regents Of The University Of California, San Diego Hif modulating compounds and methods of use thereof
EP2078096B1 (en) 2006-09-29 2010-09-01 Leukocare Ag Method for the detection of an activation of the immune system or the extent of cell death

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104479A1 (en) * 2001-08-01 2003-06-05 Cellomics, Inc. Novel fusion proteins and assays for molecular binding
US20080213800A1 (en) * 2004-05-20 2008-09-04 Astellas Pharma Inc. Method for Examing Interstitital Cystitis
WO2010022281A1 (en) * 2008-08-20 2010-02-25 Greystone Pharmaceuticals, Inc. Methods for using human neutrophil elastase as an indicator of active wound infection
US20120135443A1 (en) * 2009-06-26 2012-05-31 Schultz Gregory S Rapid Bed-Side Measurement of Neutrophil Elastase Activity in Biological Fluids
US20110082155A1 (en) * 2009-10-02 2011-04-07 Astrazeneca Ab Novel 2-Pyridone Compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2997352A4 *

Also Published As

Publication number Publication date
CN105339780A (en) 2016-02-17
WO2014144572A2 (en) 2014-09-18
US20160011209A1 (en) 2016-01-14
JP2016519761A (en) 2016-07-07
US9958459B2 (en) 2018-05-01
HK1214863A1 (en) 2016-08-05
EP2997352A2 (en) 2016-03-23
EP2997352A4 (en) 2017-03-01
CA2906124A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
Whibley et al. Beyond Candida albicans: Mechanisms of immunity to non-albicans Candida species
Pasquali et al. Genetic approaches to chemotype determination in type B-trichothecene producing Fusaria
WO2014201362A3 (en) Computer vision application processing
WO2015004241A3 (en) Multiple proteases deficient filamentous fungal cells and methods of use thereof
EP3189152A4 (en) Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
WO2014158811A8 (en) Newcastle disease viruses and uses thereof
MY189195A (en) Immunomodulatory fusion proteins and uses thereof
WO2015102707A3 (en) Compositions, methods and systems for external and internal environmental sensing
MX2023001319A (en) Conditionally active polypeptides.
WO2011113019A3 (en) Ctla4 proteins and their uses
WO2010151070A3 (en) Virtual world processing device and method
EP3339019A4 (en) LAMINATE HAVING BARRIER PROPERTIES AGAINST MOISTURE
MX2015007379A (en) Novel compounds.
WO2012087160A3 (en) Anti-inflammatory proteins and methods of preparation and use thereof
BRPI0909442A2 (en) retroreflective article of multidirectional cube corner.
ES2570902T3 (en) Aqueous product comprising microcapsules containing oil and a manufacturing process thereof
BR112013020889A2 (en) water soluble nutritional compositions comprising cereal beta-glucan and resistant starch
BR112014030025A2 (en) polysaccharide compositions and methods of use
EP3426719C0 (en) Composites with structural polysaccharides and structural proteins, produced from ionic liquid compositions
MX383129B (en) Yeast cell wall enriched in mannan oligosaccharide protein
WO2015092819A3 (en) Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5- amine
BR112014024553A2 (en) ft family nucleic acid and peptide / protein sequences providing flowering repression properties in tobacco and transgenic plants transformed therewith.
WO2011115456A3 (en) Tnf-α and tweak dual antagonist for the prophylaxis and treatment of autoimmune diseases
ITUB20160768A1 (en) Museum showcase, with detection sensors, regulation actuators, alarms and processing units connected to each other
MX2016012890A (en) Mic reduction with lithium ions.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480015786.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14762263

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14771322

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2014762263

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2906124

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2016502967

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14762263

Country of ref document: EP

Kind code of ref document: A2